UNAIDS [to 25 February 2017]

UNAIDS [to 25 February 2017]

Italy invests half a million euros to support UNAIDS’ work in Ethiopia
21 February 2017
The Italian Government signed on 21 February a financing agreement for €500 000 to support UNAIDS’ efforts to end the AIDS epidemic in Ethiopia. The funds will be invested in a special project to bolster UNAIDS’ work in improving community health education and capacity- and knowledge-building. The project will be implemented across 10 areas of the Southern Nations, Nationalities and Peoples’ Region of the country over a 12-month period…

CROI shows the importance of 90–90–90
21 February 2017
A number of important updates were announced at the annual Conference on Retroviruses and Opportunistic Infections (CROI) that have shown the importance of, and ways to achieve, the 90–90–90 targets, whereby, by 2020, 90% of people living with HIV know their HIV status, 90% of people who know their HIV-positive status are accessing treatment and 90% of people on treatment have suppressed viral loads.
Held in Seattle, United States of America, from 13 to 16 February, CROI, the foremost annual scientific research conference on HIV, brought together around 4000 scientists, researchers, clinicians, students and others working in the response to HIV and related diseases…

Industry Watch

Industry Watch

:: In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
February 24, 2017 04:00 PM Eastern Standard Time
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company’s investigational inactivated varicella zoster virus vaccine (VZV) for the prevention of herpes zoster or HZ, also known as shingles, in immunocompromised patients. This was a double-blind, randomized, placebo-controlled, multi-center trial to study safety, tolerability, efficacy and immunogenicity of inactivated VZV Vaccine in Recipients of Autologous Hematopoietic Stem Cell Transplants (auto-HSCT). In the trial, V212 met its primary endpoint and reduced the incidence of confirmed HZ cases by an estimated 64 percent (95% CI, 0.48, 0.75) in recipients of auto-HSCT. These results were presented today, as an oral presentation, at the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT) during a “Best Abstracts” session in Orlando, Florida…

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders

Reports/Research/Analysis/Commentary/Conferences/Meetings/Book Watch/Tenders
Vaccines and Global Health: The Week in Review has expanded its coverage of new reports, books, research and analysis published independent of the journal channel covered in Journal Watch below. Our interests span immunization and vaccines, as well as global public health, health governance, and associated themes. If you would like to suggest content to be included in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Immunization Financing: A Resource Guide for Advocates, Policymakers, and Program Managers
Results for Development, Washington, DC
2017 :: 128 pages
PDF: http://immunizationfinancing.org/home/Immunization_Financing_Resource_Guide_2017_FULL.pdf
This resource guide collects 26 brief documents on topics related to the cost and financing of national immunization programs in low- and middle-income countries. Some of the briefs explore possible financing sources. Others examine the components and drivers of immunization costs, planning and decision-making processes related to immunization programs and budgets, and the relationship between immunization and broader health system financing. The resource guide concludes with a set of country case studies that illustrate particular approaches or important challenges.

This volume is intended for immunization advocates, program managers, decision-makers, and planners in ministries of health and finance. The information is relevant to countries that are eligible for support from Gavi, the Vaccine Alliance, as well as to countries that are transitioning out of Gavi support and middle-income countries that have never received Gavi support.

The briefs can be read in sequential order or individually. Each begins with a summary of key
points. Some of the briefs are more technical than others, due to their subject matter, but they are all meant to convey practical information to readers who do not have specific technical expertise. Many of the briefs recommend other resources that offer more in-depth information.

Journal Watch

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.
If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

Hepatitis C virus and HIV co-infection among pregnant women in Rwanda

BMC Infectious Diseases
(Accessed 25 February 2017)

Research article
Hepatitis C virus and HIV co-infection among pregnant women in Rwanda
Hepatitis C virus (HCV) infection is a pandemic causing disease; more than 185 million people are infected worldwide. An HCV antibody (Ab) prevalence of 6.0% was estimated in Central African countries. The study aimed at providing HCV prevalence estimates among pregnant women in Rwanda.
Mwumvaneza Mutagoma, Helene Balisanga, Dieudonné Sebuhoro, Aimable Mbituyumuremyi, Eric Remera, Samuel S. Malamba, David J. Riedel and Sabin Nsanzimana
BMC Infectious Diseases 2017 17:167
Published on: 22 February 2017

A longitudinal study on determinants of HPV vaccination uptake in parents/guardians from different ethnic backgrounds in Amsterdam, the Netherlands

BMC Public Health
(Accessed 25 February 2017)

Research article
A longitudinal study on determinants of HPV vaccination uptake in parents/guardians from different ethnic backgrounds in Amsterdam, the Netherlands
Human papillomavirus (HPV) vaccination coverage in the Netherlands is low (~60%) compared to other childhood vaccinations (>90%), and even lower among ethnic minorities. The aim of this study was to explore th…
Catharina J. Alberts, Maarten F. Schim van der Loeff, Yvonne Hazeveld, Hester E. de Melker, Marcel F. van der Wal, Astrid Nielen, Fatima El Fakiri, Maria Prins and Theo G. W. M. Paulussen
BMC Public Health 2017 17:220
Published on: 21 February 2017